|
|
Start year |
End year |
Title |
Source |
Position |
| 1. |
|
2012 |
|
Phase Ib trial for active lupus Medi 545 |
Medimmune |
PI |
| 2. |
|
2012 |
|
SLE Criteria Revision Project (AROSE) |
#NIH 1RO1-AR49125-01 subcontract |
SI |
| 3. |
|
2012 |
|
Pregnancy Outcome in Lupus and APS |
#NIH R01- AR049772-01 subcontract |
SI |
| 4. |
|
2012 |
|
Apheresis for Active Lupus PHASE I STUDY |
Otsuka Pharmaceuticals Site |
PI |
| 5. |
|
2012 |
|
#Belimumab for SLE PHASE II and III Studies and longterm followup |
Human Genome Sci |
PI |
| 6. |
|
2012 |
|
BAFF antagonist Phase Ia and Ib pharmacokinetic study in SLE |
Amgen |
PI |
| 7. |
|
2012 |
|
Rituximab for SLE |
Genentech-Biogen/IDEC |
PI |
| 8. |
|
2012 |
|
Orencia for non renal SLE |
Bristol Myers Squibb |
PI |
| 9. |
|
2012 |
|
Rituximab for nephritis in SLE |
Genentech-Biogen/IDEC |
PI |
| 10. |
|
2012 |
|
Phase I trial of IFN alpha antagonist for mild SLE |
Medimmune |
Lead Investigator |
| 11. |
|
2012 |
|
#Biologic Markers of Plasmapheresis |
Bio-Rad |
PI |
| 12. |
|
2012 |
|
Phase Ib trial for active lupus Medi 545 |
Medimmune |
Lead Investigator |
| 13. |
|
2012 |
|
Investigator-initiated study of Cellcept for lupus arthritis |
Aspreva |
PI |
| 14. |
|
2012 |
|
Phase I trial for INF alpha inhibitor |
Genentech |
PI |
| 15. |
|
2012 |
|
CTLA4Ig in Lupus Nephritis |
Immune Tolerance Network ITN034A1 |
PI |
| 16. |
|
2012 |
|
LCTC database of SLE |
#Lupus Clinical Trials Consortium |
PI |
| 17. |
|
2012 |
|
Ancillary Clinical Studies Addressing Outcomes |
Measures Research |
PI |
| 18. |
|
2012 |
|
Rontilizumab for SLE Genentech Phase II and open label extension |
ROSE study |
PI |
| 19. |
|
2012 |
|
Anti-BLyS/BAFF agent for SLE Anthera Phase II |
PEARL study |
PI |
| 20. |
|
2012 |
|
Epratuzumab for SLE (anti-CE22) UCB Phase III |
Embody Trial |
PI |
| 21. |
|
2012 |
|
Anti-BLyS/Baff for SLE Lilly Phase III study |
Illluminate study |
PI |
| 22. |
|
2012 |
|
Validation of the Lupus QOL: GSK |
# Patient Reported Outcomes in SLE |
PI |
| 23. |
|
2012 |
|
validation of SLE flare criteria/outcome measures |
EULAR grant |
Co PI |
| 24. |
|
2012 |
|
DHEA in prednisone-dependent SLE, and mild-moderate SLE |
Genelabs Inc. |
SI |
| 25. |
|
2012 |
|
DHEA in mild-moderate SLE |
Genelabs Inc |
SI |
| 26. |
|
2012 |
|
WinRhoD in SLE thrombocytopenia |
NABI Inc |
PI |
| 27. |
|
2012 |
|
LJP 394 in patients with SLE and history of nephritis |
Abbott/ La Jolla Pharmaceuticals |
SI |
| 28. |
|
2012 |
|
Safety of OCP in SLE |
NIH RO1 subcontract |
PI |
| 29. |
|
2012 |
|
Safety of HRT in SLE |
NIH RO1 subcontract |
PI |
| 30. |
|
2012 |
|
DHEA for men with SLE |
Genelabs Inc |
PI |
| 31. |
|
2012 |
|
LJP 394 in patients with SLE and dsDNA antibodies |
Abbott/La Jolla Pharmaceuticals |
PI |
| 32. |
|
2012 |
|
DMP777 Neutrophil Elastase Inhibitor for lupus |
Dupont Inc |
PI |
| 33. |
|
2012 |
|
Complement split products in SLE |
NIH R01 subcontract: quality assurance monitor. |
|
| 34. |
|
2012 |
|
BG9588 Anti-CD40 Ligand for active lupus |
Biogen Inc |
PI |
| 35. |
|
2012 |
|
IDEC 131 for patients with active lupus |
IDEC Inc. |
PI |
| 36. |
|
2012 |
|
CellCept vs. Cyclophosphamide for Lupus Nephritis |
FDA orphan drug trial |
PI |
| 37. |
|
2012 |
|
LJP 394 second trial for patients with SLE, nephritis history |
La Jolla Pharmaceuticals |
PI |
| 38. |
|
2012 |
|
#Systemic Lupus International Collab Clinics Atherosclerosis Study |
SLICC consortium: |
PI |
| 39. |
|
2012 |
|
#Registry for Patients with the Antiphospholipid Syndrome |
supported by small pharma/biotech contracts |
PI |
| 40. |
|
2012 |
|
LJP 1082 for the Antiphospholipid Syndrome PHASE I STUDY |
La Jolla Pharmaceuticals |
PI |
| 41. |
|
2012 |
|
Anti-Blys for Lupus PHASE I STUDY |
Human Genome Sci. |
PI |
| 42. |
|
2010 |
2012 |
B Cell Biology in Patients with SLE |
Morphotech |
|
| 43. |
|
2009 |
2012 |
Pfizer Medication Effects on Biomarkers |
Biomarkers of Lupus Disease |
PI |
| 44. |
|
2002 |
2012 |
Pheresis studies in patients with auto-antibodies |
Bio-Rad |
PI |
| 45. |
|
2006 |
2011 |
Basic Research Linked to study of Rituximab in RA |
Genentech |
SI |
| 46. |
|
2005 |
2008 |
Genetics of Platelet Dysfunction in APS |
OCAST Health Research |
PI |
| 47. |
|
2002 |
2007 |
Linked to Apheresis Trial below |
Otsuka Pharmaceuticals Basic Research |
PI |
| 48. |
|
2002 |
2007 |
Polymorphisms of APS Antigens (basic genetics research ) |
NIH NIAMS RO1 |
PI |
| 49. |
|
2001 |
2006 |
Effects of Oral Contraceptives on protein S in lupus patients (basic research subcontract linked to a clinical trial) |
NIH NIAMS RO1 subcontract |
PI |
| 50. |
|
2001 |
2003 |
Functional significance of APS antigen polymorphisms |
SLE Foundation Inc |
PI |
| 51. |
|
2000 |
2003 |
Pathologic Epitopes of ApoA1 Antibodies |
The SLE Foundation Inc |
PI |
| 52. |
|
1998 |
2003 |
Sporadic Mechanism of APLS |
NIH NIAID RO1 AI42110-01A1 |
PI |
| 53. |
|
2001 |
2002 |
Thrombotic risk of polymorphisms in APLS |
OCAST Health Research |
PI |
| 54. |
|
2000 |
2001 |
Pathologic coagulation effects of anti-CD40 Ligand |
IDEC, Inc |
|
| 55. |
|
1997 |
2000 |
Protein S Function in APLS |
The SLE Foundation Inc |
PI |
| 56. |
|
1996 |
1997 |
Colchicine-Mechanism in RA |
NY Arthritis Foundation |
PI |
| 57. |
|
1994 |
1997 |
Integrin Responses to Mtb |
NIH K08 award |
PI |
| 58. |
|
1994 |
1996 |
Complement Activation in APLS |
The SLE Foundation Inc |
PI |
| 59. |
|
1993 |
1995 |
Integrin Function in RA |
NY Arthritis Foundation |
PI |
| 60. |
|
1992 |
1994 |
#U19 AI082714 Autoimmunity Centers of Excellence |
NIH |
PI |
| 61. |
|
1992 |
1994 |
Integrin Responses to Mtb |
Stony Wold Herbert Fund |
PI |
| 62. |
|
1991 |
1992 |
NIH P20 RR015577 COBRE grant |
NIH |
PI |
| 63. |
|
1991 |
1992 |
Integrin Activation |
NY Arthritis Foundation |
Fellowship |
How We Rank
